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Abstract
Background: The etiology of Balkan Endemic Nephropathy, (BEN), a tubulointerstitial kidney disease, is
unknown. Although this disease is endemic in rural areas of Bosnia, Bulgaria, Croatia, Romania, and Serbia,
similar manifestations are reported to occur in other regions, for instance Tunisia and Sri Lanka. A number
of explanations have been stated including lignites, aristolochic acid, ochratoxin A, metals, and metalloids.
Etiologic claims are often based on one or a few studies without sound scientific evidence. In this
systematic study, we tested whether exposures to metals (cadmium and lead) and metalloids (arsenic and
selenium) are related to Balkan Endemic Nephropathy.
Methods: In 2003/04 we recruited 102 adults whose parents had BEN and who resided in one of three
communities (Vratza, Bistretz, or Beli Izvor, Bulgaria). A control group comprised of 99 adults having non-
BEN hospitalized parents was enrolled in the study during the same time. We conducted face-to-face
interviews, ultrasound kidney measurements, and determined kidney function in two consecutive
investigations (2003/04 and 2004/05). Metals and metalloids were measured in urine and blood samples.
To assess the agreement between these consecutive measurements, we calculated intraclass correlation
coefficients. Repeated measurement data were analyzed using mixed models.
Results: We found that cadmium and arsenic were associated with neither kidney size nor function. Lead
had a significant but negligible effect on creatinine clearance. Selenium showed a weak but significant
negative association with two of the four kidney parameters, namely creatinine clearance and β2-
microglobulin. It was positively related to kidney length. These associations were not restricted to the
offspring of BEN patients. Adding credence to these findings are reports showing comparable kidney
effects in animals exposed to selenium.
Conclusion: The findings of this 2-year follow-up study indicate that metals and metalloids do not play a
role in the etiology of Balkan Endemic Nephropathy. Against the assumption in the literature, selenium
was not protective but a risk factor. Since comparable associations were observed in animals, future
studies are needed to explore whether selenium may have adverse renal effects in humans.
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Background
Balkan Endemic Nephropathy (BEN) is a tubulointersti-
tial kidney disease that progresses slowly over many years.
First characterized in the Vratza District, Bulgaria in 1956
[1], similar nephropathies were subsequently described in
Yugoslavia [2,3] and in Romania [4]. In 1964 this disease
was recognized as a new nosological entity and named
Balkan Endemic Nephropathy. The final disease stage is
characterized by renal failure and shrinkage of both kid-
neys to the size of walnuts [5]. BEN shows familial cluster-
ing and develops only in certain areas in the Balkan
countries – Bulgaria, Romania, Serbia, Montenegro,
Croatia, and Bosnia and Herzegovina. Its spatial distribu-
tion shows a mosaic-like pattern, with some villages
afflicted for decades, whereas others situated in the same
vicinity have remained free of BEN [6-8]. It is still
unknown what causes BEN. Although this disease is
endemic in rural areas of the Balkan, endemic nephropa-
thies are reported to occur in other regions. For instance,
chronic kidney diseases of uncertain etiology, which
resemble BEN, have been reported in Sri Lanka (personal
communication, Dr. Alturaliya, Sri Lanka). Every now and
then, new explanations emerge emphasizing lignites [9],
aristolochic acid [10], ochratoxin A [11], metals, and met-
alloids [12-15]. However, these claims are often not sub-
stantiated by sufficient evidence or scientific studies. For
instance, studies claim that exposures to metals (cad-
mium and lead) and metalloids (arsenic and selenium)
are related to the disease, with selenium being protective
[12-15].
An important characteristic of BEN is the late onset of the
disease (not before age 50) and thus probably a long
latency period and/or a period of being at risk between
exposure and the gradually developing clinical manifesta-
tion of the disease. To determine exposures before the
onset of the disease, we chose to study the offspring of
patients with BEN, who are at a higher risk for the disease,
and use the offspring of other non-BEN patients as a con-
trol group.
Early markers for BEN are a lower creatinine clearance,
increased excretion in urine of total protein, albumin, and
β2-microglobulin, and symmetrically decreased kidney
measures [16-27]. We recently reported in a cross-sec-
tional investigation that changes in these markers are
associated with being offspring of BEN parents [28]. In
this work we link clinical markers with the concurrent
burden of metals and metalloids.
We investigated four metals and metalloids: lead, arsenic,
cadmium, and selenium. Lead, absorbed in blood, is
bound extensively to erythrocytes (90–95%) and lead
content in whole blood is used routinely as a biomarker
of exposure (up to a few months before sampling)
[29,30]. Most arsenic absorbed by the lungs or by the gas-
tro-intestinal tract is excreted in the urine, mainly within
1–2 days. Measurement of urinary arsenic levels is gener-
ally accepted as the most reliable indicator of recent expo-
sure [31]. Total arsenic in urine, which is measured in this
study, includes inorganic arsenic, as well as its metabolites
monomethylarsonic acid and dimethylarsinic acid.
Cadmium is a heavy metal which accumulates predomi-
nantly in the kidneys (half-life: 15–40 years) and liver and
is excreted mainly in urine. In low-level exposures (below
10  μg/g creatinine) cadmium content in urine reflects
body burden and is used as a biomarker of cumulative
exposure [30,32]. After absorption, selenium in blood is
distributed between red blood cells and plasma/serum.
The concentration in plasma or serum is considered to
reflect short-term exposure, whereas the selenium content
of erythrocytes indicates long-term exposure [32]. In a
steady state, the Se levels in red blood cells are considered
to be higher than those in serum [33,34], however, both
are significantly correlated and comparably associated
with daily intake [35-37]. Serum selenium is used for
assessment of occupational and environmental selenium
exposure, including nutritional status, in various studies,
for instance, the U.S. National Health and Nutrition
Examination Survey [32,38,39].
Based on prior reports in the BEN literature we formulated
five hypotheses:
1) Selenium serum concentration is protective against
adverse kidney effects.
2) Lead in blood, 3) cadmium in urine, and 4) arsenic in
urine are associated with adverse alterations in BEN kid-
ney markers and size.
5) Adult offspring with a parental history of BEN show
stronger associations between metals and/or arsenic and
kidney variables.
Since the incidence of BEN shows a spatial distribution
with a mosaic-like pattern one may consider to simultane-
ously compare residents from BEN villages and non-BEN
villages and specific exposures. By doing so, we could
compare combined effects of residence and of specific
exposures. This would be advantageous, since we would
also control for unknown risk factors acting in BEN vil-
lages. However, we need to take into consideration that
we do not have BEN patients from non-BEN villages (Fig-
ure 1). Thus, a formal testing of interaction terms will not
work. Alternately, if we compare the effect of metals in
BEN-offspring from BEN villages with the effect of metals
in non-BEN offspring from non-BEN villages, we would
mix two effects: the specific metal effect and an unknownEnvironmental Health 2008, 7:11 http://www.ehjournal.net/content/7/1/11
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spatial effect, which would result in confounding. To esti-
mate spatial effects, ecological studies have been con-
ducted and have attributed differences to specific factors
[14]. We considered that testing of specific risk factors
requires a more rigorous comparison, namely of offspring
of BEN and non-BEN patients from BEN villages.
Methods
Study Population
From October, 2003, to April, 2004, we recruited 102
adults whose father and/or mother were registered in the
Vratza Hospital as BEN patients and who resided in one of
three communities (Vratza, Bistretz, or Beli Izvor, Bul-
garia). The parental diagnosis of BEN was based on epide-
miological, clinical/laboratory, and pathological/
anatomical criteria [40]. Regarding epidemiology, the
region is known to have a high prevalence of BEN. The
individual criterion is onset after the age of 50. Clinical
and laboratory criteria are as follows: obscure onset,
chronic course, absence of edema, and normochromic
anemia in the more advanced phases. Pathologically, an
almost symmetrical macroscopic shrinkage of the two kid-
neys is found. A control group of nearly equal size, 99
adult offspring of non-BEN hospitalized patients was
enrolled at the same time. Diagnoses in control parents
included diabetes mellitus, cardiovascular disorders, and
liver problems. Only three of the 99 control subjects had
parents with kidney diseases (one paternal kidney cancer
not related to BEN and two maternal pyelonephritis
cases). Subjects of both groups were frequency-matched
according to gender and ten-year age groups. The popula-
tion was enrolled and examined in 2003/04 and re-exam-
ined in 2004/05, which provided us with two repeated
measurements one year apart.
All participants provided written consent through a proce-
dure approved by the Institutional Review Board (human
subject research committee) of the National Center of
Public Health Protection, Sofia, Bulgaria. This research
was reviewed and approved by the Commission of Medi-
cal Ethics at the National Center of Hygiene, Medical Ecol-
ogy and Nutrition, Sofia, Bulgaria, on December 16,
2002.
Interviews
We conducted face-to-face interviews with all participants,
either in the hospital or by visiting them in their home vil-
lages. The standardized questionnaire asked for the place
of residence, type of water supply, diet, smoking and
drinking habits, medical symptoms, family history of
BEN, family history of other kidney diseases and kidney
tumors, and occupational history.
Physical examination and determination of kidney sizes
Physical examinations, performed by an experienced phy-
sician with board certification in internal diseases and
nephrology, assessed the general health status of the study
subjects, including height and weight, and looked for
symptoms of BEN and/or other internal diseases. Blood
pressure was measured according to standards set by the
World Health Organization [41].
Ultrasound examination of both kidneys included the
patient lying on the left side and then on the right side,
and took 20–30 minutes. The longest dimension of the
kidney, the thickness of the kidney parenchyma (in the
thinnest or minimal part), and the relationship of paren-
chyma and pyelon were measured. Data gathered also
included parenchyma structure and the location, size, and
morphology (cysts, stones, and tumors) of the kidneys.
The images were saved electronically for future reference.
The ultrasonographer (AGB) worked in the Department
of Image Diagnostics, Vratza District Hospital, and was
blinded to the clinical status of the participant (BEN or
control offspring).
Urine and blood collection and determination of kidney 
markers
Prior to the examination day, study subjects were pro-
vided with 100 mL polypropylene containers and
instructed to collect their urine, avoiding external contam-
ination, immediately after rising in the morning and to
take it to the laboratory without delay. They were also told
to refrain from eating fish, seafood, chicken, and organ
meat during the week before sample collection in order to
diminish their intake of organic arsenic via diet. At the
laboratory, aliquots of the first morning urine sample
were transferred to polypropylene tubes: one aliquot was
used for the measurement of creatinine; the other two
were acidified with either 1N HCl (Merck) for arsenic
determination or 1N HNO3 (Merck) for cadmium deter-
mination. Then the aliquots were frozen at -20°C.
After the morning urine collection, the participants under-
went a 4-hour examination with urine and blood sam-
pling. Study subjects were asked to empty their bladders
Study designs for Balkan Endemic Nephropathy Figure 1
Study designs for Balkan Endemic Nephropathy.
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and were given 0.5 L of water to drink. From that moment
on, all their urine was collected in polyethylene contain-
ers and refrigerated: At the end of the 1st hour and at 4
hours the study subjects were asked to urinate. Venous
blood was collected after 2 hours.
The hour-one urine was checked with pH-indicator paper
strips (Merck). If the pH was lower than 7, a portion of the
urine was alkalized by adding 1N NaOH until a pH equal
to 7 or between 7 and 8 was reached. Creatinine and β2-
microglobulin were measured in aliquots of the hour-one
urine sample. The volume of the hour-one urine sample
was taken into account when the total urine volume was
recorded at the end of the 4-hour period. The total 4-hour
urine sample was apportioned into aliquots and frozen at
-20°C. As described elsewhere [28], we determined total
protein, albumin, and creatinine in urine in the 4-hour
sample. To adjust for creatinine concentration, it was
measured three times: in the first morning, the hour-one,
and the 4-hour samples.
Venous blood for hematology, the determination of lead,
and for serum separation was taken in the middle of the
4-hour urine collection period. Blood samples for deter-
mination of lead were drawn in K2EDTA vacutainers.
Serum was separated for the analyses of selenium and cre-
atinine.
Creatinine clearance
Creatinine clearance (CCR) was estimated from serum
creatinine values by using the Cockcroft and Gault (1976)
formula [42]. Specifically,
We adjusted CCR by dividing through body surface area
[= square root ((height in cm × weight in kg)/3600)].
Analyses of trace elements
Lead, cadmium, arsenic, and selenium were determined
using Perkin-Elmer atomic absorption spectrometers
(Bodenseewerk Perkin-Elmer, Ueberlingen, Germany). A
Model 4110 ZL atomic absorption spectrometer (AAS)
with a transverse heated graphite atomizer (THGA) and
longitudinal Zeeman-effect background correction
equipped with an AS-72 autosampler, electrodeless dis-
charge lamps (EDL) System II, software WinLab (Version
1.2) and both "Standard" (Part No B 300–0643) and
"End-capped" (Part No B 300–0644) THGA tubes with
integrated platforms was used for direct electro-thermal
AAS measurements of lead in blood, selenium in serum,
and cadmium in urine. A Model 3030 AAS with a Mer-
cury/Hydride System MHS-20, automatic deuterium
background corrector and EDL System II was used for
direct hydride generation AAS determinations of arsenic
(As) in urine.
To measure lead (Pb), blood was diluted 10-fold with
0.25% v/v Triton X-100; 10 μL of the sample and 25 μg of
(NH4)2HPO4 as a chemical modifier were injected into
the THGA, pre-treated with 250 μg of zirconium and 20
μg of iridium [43]. For selenium (Se), serum was diluted
5-fold with 0.1% v/v Triton X-100 in 0.2% HNO3; 10 μL
injections of the sample and 10 μg of rhodium modifier
were injected into the THGA; standard addition calibra-
tion was applied [44]. For cadmium (Cd) in urine, the
samples were diluted 5-fold with 0.05 v/v Triton X-100 in
0.2% HNO3; 10 μL of the sample and 25 μg of
(NH4)2HPO4 as a chemical modifier were injected into
the THGA, pre-treated with 250 μg of zirconium and 20
μg of iridium [43]. Matrix-matched calibrations were
applied for Pb, Se, and Cd. Total As was determined after
transformation of the inorganic arsenic, As(III) + As(V),
monomethylarsonate and dimethylarsinate, into simi-
larly reactive species by treatment with L-cysteine. The
final dilution of the urine samples was 5-fold. 10 mL aliq-
uots were directly analyzed by hydride generation AAS
[45].
We used the following reference materials for trace ele-
ments: Lyphochek Urine Metals Control Level 1, Cat. No.
400 (Bio-Rad Laboratories, Germany); Seronorm Trace
Elements Urine Blank Cat. No. 201305; Seronorm Trace
Elements Serum Level 1, Cat. No. 201405, and Level 2,
Cat. No. 203105; Seronorm Trace Elements Whole Blood,
Level 1, Cat. No. 201505, and Level 2, Cat. No. 201605
(Sero AS, Norway).
Statistical analyses
Outcome variables were total protein, albumin, β2-
microglobulin, creatinine in serum, CCR, kidney cortex
width, and kidney length. To answer the question whether
these outcomes are related to selenium serum concentra-
tion, lead in blood, and cadmium and arsenic urine excre-
tion, we controlled for potentially confounding factors
such as gender, age, history of smoking, diabetes mellitus,
hypertension, body surface area (BSA), and creatinine in
the morning urine sample, the 1-hour, and the 4-hour
urine samples. We defined hypertension (Table 1) accord-
ing to the The Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure [46]. For smoking, we
distinguished between current smoker, ex-smoker, and
non-smoker. We asked for presence of diabetes mellitus
and determined hypertension in the first investigation
(2003/04) and for new occurrence in the second investi-
gation. BSA was used in the model to control for the effect
of weight and height on kidney markers. In each investi-
gation (2003/04 and 2004/05) the average kidney cortex
CCR ml
age body weight in kg
serum creatinine
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width and kidney length of both kidneys were used as pre-
dictors.
In order to estimate the association between repeated
measurements of arsenic, cadmium, lead, selenium, and
kidney markers, we applied linear mixed models. Meas-
urements of the two investigations are not independent
and mixed models allowed for adjusting for within-partic-
ipant effects [47]. The mixed model assumes that the ran-
dom effects and the error vector are normally distributed,
which was the case for kidney sizes and CCR; β2-microb-
lobulin was log-transformed. SAS PROC MIXED was used
to perform the regression analysis [48]. We used the
Akaike information criteria and likelihood ratio tests to
examine the significance of serial correlation (repeated
statement) as well as to model random effects, along with
a suitable variance-covariance matrix structure. To investi-
gate whether offspring with a parental history of Balkan
Endemic Nephropathy are more susceptible to metals and
metalloids, we additionally stratified the models by
parental history.
To compare the agreement between measurements of
continuous variables in 2003/04 and 2004/05 we used
the intra-class correlation coefficient (ICC). This is the
between-subject minus the within-subject variance
divided by the sum of the two variances. The ICC quanti-
fies the proportion of total outcome variance that is due
to inter-individual variation. A positive value, for
instance, of 0.60 indicates that 60% of the variation is due
to between-subject and 40% due to within-subject vari-
ance. ICC can become negative when the within-subject
variance exceeds the between-subject variance. Due to
methodological considerations [49], we chose not to
directly adjust for creatinine using creatinine-adjusted
parameters but to introduce creatinine as a confounder in
the regression models.
Results
Of the 201 participants from the first year, 189 partici-
pated in the follow-up (94%). Two were deceased, one
moved out of the area, two could not be contacted, and
seven decided not to participate further. Of the twelve lost
nine were offspring of BEN patients. With the exception of
hypertension, potential risk factors show similar distribu-
tions in each of the two investigations (Table 1). Of the
BEN offspring, 30.4% had hypertension in 2003/04 and
29% in 2004/05. A lower prevalence was detected in con-
trol offspring (19.2 and 22.9%, respectively). BEN
patients also reported more often a history of kidney
stones and pyelonephritis.
Regarding arsenic and cadmium (measured in morning
urine) and creatinine (measured in morning urine sam-
Table 1: Characteristics of the Cohort of Adult Offspring of BEN Patients and Controls
2003/04 2004/05
Offspring of BEN 
patients, n = 102 (%)
Offspring of control 
patients, n = 99 (%)
Offspring of BEN 
patients, n = 93 (%)
Offspring of control 
patients, n = 96 (%)
Gender Men 50.0 47.5 48.8 47.9
Age 30–40 32.4 15.5 32.3 15.6
41–55 43.1 57.6 43.0 58.3
56 plus 24.5 27.3 24.7 26.0
Place of birth BEN village 95.0 72.7 94.6 72.9
Smoking status current smoker 39.2 34.4 38.7 35.4
ex-smoker 22.6 12.1 21.5 12.5
non-smoker 38.2 53.5 39.8 52.1
Diabetes 7.8 6.1 5.4 7.3
Hypertension in the 
offspring ξ
30.4 19.2 32.3 22.9
Other urinary tract 
diseases
kidney cancer 2.0 0 2.2 0
kidney stones 10.8 4.0 10.8 6.5
Pyelonephritis 10.8 0 9.7 1
Hydronephrosis 1 0 1 0
Cystitis 3.9 5.1 5.4 5.2
BSA # mean 
(standard deviation)
1.87 (0.22) 1.82 (0.21) 1.86 (0.18) 1.81 (0.17)
ξ Systolic blood pressure ≥ 140 and/or diastolic ≥ 90 mm Hg [41]
# BSA = square root ((height in cm × weight in kg)/3600).
The intraclass correlation coefficient (ICC) is the between- subject minus the within- subject variance as a ratio to the sum of the two variances. A 
positive value of, for instance, 0.60 indicates that 60% of the variation is due to between-subject and 40% due to within-subject variance. ICC can 
become negative when the within-subject variance exceeds the between-subject variance.Environmental Health 2008, 7:11 http://www.ehjournal.net/content/7/1/11
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ples), we found no agreement between the two investiga-
tions for creatinine, a moderate agreement for arsenic and
a good agreement for cadmium (Spearmen rank correla-
tion and ICC, Table 2). For creatinine in morning urine
samples the within-subject variance exceeds the between-
subject variance. When we used the directly creatinine-
adjusted parameters (division by the creatinine concentra-
tions) the agreement for cadmium and arsenic was
reduced, simply because of the high intra-individual vari-
ance of creatinine. There was a better agreement for two
measurements, namely lead in blood and selenium in
serum, measured one year apart.
Regarding the kidney parameters, Spearman rank correla-
tion and ICC were low for total protein and albumin in
serum, for creatinine in the 1-hour and 4-hour urine sam-
ple, and for the glomerular filtration rate (Table 3). These
values did not improve when we directly adjusted for cre-
atinine, since the within-subject variance of creatinine was
high. The agreement between the sonographic determina-
tions of kidney dimensions (kidney cortex and kidney
length), β2-microglobulin, and the estimated creatinine
clearance (CCR) was sufficient to conclude that they
measure some underlying disease processes. In the follow-
ing analyses we focus on these four parameters to test
whether arsenic and metals explain their variance.
Table 2: Metals and metalloids in urine and serum in two consecutive investigations
Variable N Median 5%-value 95%-value Spearman correlation coefficient (p) ICC ICC 5%-value
As in urine (μg/L) 2003/04 201 3.10 0.70 9.30 0.28 (0.0001) -0.06 -0.18
2004/05 189 2.90 0.80 8.90
Cd in urine (μg/L) 2003/04 201 0.60 0.15 2.15 0.48 (< 0.0001) 0.44 0.34
2004/05 189 0.70 0.27 1.91
Creatinine in morning urine (g/L) 2003/04 201 0.72 0.15 1.80 -0.06 (0.40) -0.47 -0.56
2004/05 189 0.75 0.10 1.95
Pb in blood (μg/L) 2003/04 201 90.90 47.10 213.00 0.70 (< 0.0001) 0.69 0.62
2004/05 189 85.00 39.10 203.00
Se in serum (μg/L) 2003/04 201 56.90 36.00 78.50 0.45 (< 0.0001) 0.17 0.05
2004/05 189 72.10 46.40 95.70
The intraclass correlation coefficient (ICC) is the between- subject minus the within- subject variance as a ratio to the sum of the two variances. A 
positive value of, for instance, 0.60 indicates that 60% of the variation is due to between-subject and 40% due to within-subject variance. ICC can 
become negative when the within-subject variance exceeds the between-subject variance.
Table 3: Clinical markers of kidney function in two consecutive investigations
Variable N Median 5%-value 95%-value Spearman correlation coefficient (p) ICC ICC 5%-value
Total protein in urine (mg/L) 2003/04 201 30.0 10 140 -0.03 (p = 0.73) 0.03 -0.09
2004/05 189 13.5 0 86
Albumin in urine (mg/L) 2003/04 201 5.9 0.9 36 0.05 (0.53) -0.14 -0.26
2004/05 188 1.0 0.9 17
β2-micro-globulin in urine (ng/mL) 2003/04 201 25.1 7.3 171 0.41 (< 0.0001) -086 -0.89
2004/05 189 37.5 12.5 244
Creatinine in 1-hour urine (g/L) 2003/04 188 0.27 0.06 1.23 0.29 (p < 0.001) 0.23 0.11
2004/05 189 0.44 0.11 1.7
Creatinine in 4-hour urine (g/l) 2003/04 201 0.19 0.05 1.43 0.05 (0.47) -0.04 -0.16
2004/05 189 0.13 0.03 0.54
Glomerular filtration rate/BSA# 2003/04 200 59.8 22.4 292 0.07 (0.33) -0.16 -0.27
2004/05 189 41.5 5.6 144
CCR (Cockcroft & Gault)/BSA# 
(mL/min/m2)
2003/04 199 58.2 41.6 79.7 0.264 (< 0.0003) 0.24 0.12
2004/05 189 54.4 38.4 87.0
Kidney length (average of both) 
(mm)
2003/04 201 118.5 106 128.5 0.91 (< 0.0001) 0.92 0.9
2004/05 189 118 106.5 129.5
Minimal kidney cortex width 
(average) (mm)
2003/04 201 16.0 12 18.5 0.68 (< 0.0001) 0.66 0.58
2004/05 189 15.5 12 19
# BSA = square root ((height in cm × weight in kg)/3600)E
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Table 4: Association of metals and metalloids with β2-microglobulin, creatinine clearance, and kidney length controlling for confounders
β2-microglobulin (ng/mL) CCR Cockcroft, Gault/BSA (mL/min/m2) Kidney length (mm)
Total sample Ben-offspring Control-
offspring
Total sample Ben-offspring Control-
offspring
Total sample Ben-offspring Control-
offspring
n = 201, obs = 
387
n = 102, obs = 
192
n = 99, obs = 
195
n = 201, obs = 
388
n = 102, obs = 
193
n = 99, obs = 
195
n = 201, obs = 
388
n = 102, obs = 
193
n = 99, obs = 
195
Intercept 1.260 0.992 1.358 98.33 88.30 105.97 100.32 98.41 99.91
Blood lead (μg/L) -0.001 -0.001 -0.001 -0.02 0.01 -0.06* 0.005 -0.01 0.00
Selenium in serum (μg/L) 0.001 0.003* 0.000 -0.09* -0.05 -0.14* 0.02* 0.04* 0.01
Cadmium in urine (μg/L) 0.042 0.074 0.003 -2.09 -2.98 -1.53 0.10 0.11 0.05
Arsenic in urine (μg/L) 0.001 0.001 0.002 0.18 0.37 0.17 -0.06 -0.11 -0.07
Sex, male 0.189* 0.235* 0.151* 8.88* 4.70 13.09* 1.92 1.19 2.45
Age (years) 0.004* 0.008* 0.002 -0.67* -0.57* -0.69* 0.01 -0.02 0.02
Current smoker -0.095* -0.233* -0.004 -0.30 2.89 -3.01 0.29 2.77* -0.48
Ex-smoker 0.024 -0.059 0.039 -1.53 3.57 -8.33* -0.12 0.98 -0.09
Diabetes mellitus 0.058 0.210 -0.063 -2.10 -2.99 -3.99 -1.87 -4.01 -0.25
Hypertension 0.048 -0.040 0.100 1.11 -0.11 2.42 -0.89 0.53 -1.72
Body surface area # -0.174 -0.139 -0.116 - - - 8.58* 8.74* 9.55*
Cystitis 0.014 0.032 -0.010 0.01 4.07 -1.41 -0.67 -1.07 -0.42
Pyelonephritis -0.081 -0.118 0.191 2.39 2.33 -14.38 -0.65 0.77 -0.50
Kidney stone(s) 0.017 0.014 0.123 2.34 2.57 1.62 -0.57 -1.53 0.18
Creatinine in 1-hour urine 0.475* 0.417* 0.530* - - -
Creatinine in morning urine (g/L) 0.018 0.004 0.006 -2.81* -2.04 -3.57 -0.07 0.35 -0.28
*p ≤ 0.05
# BSA = square root ((height in cm × weight in kg)/3600)Environmental Health 2008, 7:11 http://www.ehjournal.net/content/7/1/11
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We did not find any significant effect of arsenic and metals
on kidney cortex width (Table 4). Of the metals and met-
alloids analyzed, only selenium showed an association
with kidney length, β2-microglobulin, and the estimated
CCR in the models presented in Table 4. Lead gained
importance only in the control offspring. Similar to sele-
nium, it seems to decrease CCR.
Higher selenium levels are associated with a longer kidney
length in the total group and the BEN offspring. When
comparing an individual with 70 μg/L with one having 20
μg/L selenium, on the average kidney length would be
increased by 1 mm (50 *0.02 mm). This is only a small
increase compared to the total kidney length (approxi-
mately 120 mm). However, in BEN offspring the respec-
tive increase is 2 mm (50 *0.04 mm; Table 4). Selenium
seems to decrease CCR in the total group and the control
group, but not in BEN offspring. When comparing an
individual with 70 μg/L with one having 20 μg/L serum
selenium, CCR would be reduced by 4.5 mL/min/m2 (50
*0.09 mL/min/m2) in the total group. This is a minimal
decrease of CCR (range: 54–87 mL/min/m2). In the con-
trol group, lead is associated with a decrease (0.14 mL/
min/m2).  β2-microglobulin was log-transformed to
achieve a normal distribution. A 50 μg/L increase in sele-
nium would be approximately equivalent to a 1.4%
increase in β2-microglobuline [10(50*0.003)].
Discussion
Of elements investigated, cadmium and arsenic were asso-
ciated neither with kidney dimension nor with function
(hypotheses 3 and 4). Lead had a negligible effect on CCR
(hypothesis 5). Selenium showed weak but significant
associations with three of the four kidney parameters
tested, namely kidney length, estimated CCR, and β2-
microglobulin, but not kidney cortex width.
Our study included only BEN villages. Others think that
the soil geochemistry in villages affected and not affected
by BEN may be an etiologic factor [14]. It has been sug-
gested that arsenic, cadmium, and lead (Pb) are elevated
in the soil of BEN areas, whereas selenium is deficient
[12,14,50]. Ecological studies do not take individual
exposures into account. Nevertheless, according to these
investigations, we would have expected higher levels of
arsenic, cadmium, and lead in our participants. To exam-
ine whether the levels in our samples were different, we
compared these to other reports on metal and metalloid
exposures in Bulgaria. Tsolova et al., when studying cop-
per-smelter workers, described urine arsenic concentra-
tion of 7.73μg/L in a control group [51]. We found
approximately 3μg/L in an unexposed population (Table
2). Regarding cadmium, two Bulgarian investigations
reported urine levels of 0.8–1.0μg/L [52,53]; we had urine
concentrations of 0.6–0.7μg/L. However, adjusted for cre-
atinine, urinary cadmium levels were higher in our Bul-
garian samples (approximately 0.85μg/g creatinine) than
levels reported for the United States (0.26μg/g creatinine)
[54]. Lead blood concentration in our samples was lower
(median of 90 μg/L in 2003/4, Table 3) than levels
reported for occupational exposures in Bulgaria [53,55].
Selenium levels in this study (range 36–95 μg/L, medians:
56.9 and 72.1; Table 2) were comparable to levels
reported in other studies in Bulgaria (57 and 66.5 μg/L)
[30,56]. However, serum selenium levels seems to be
lower in this rural region of Bulgaria compared to other
countries [57,58]. For instance, in the United States, mean
selenium levels were 125.7 μg/L. However, in rural
regions selenium serum levels are lower; in central France
on average 79 μg/L and in sample of rural Serbia on aver-
age 38.2 μg/L [57,59]. These concentrations are within the
95% confidence limit of our study (Table 2). In summary,
concentrations of arsenic, cadmium, lead, and selenium
in our samples were either comparable to concentrations
in samples taken from other subpopulations in Bulgaria.
Hence, these comparisons do not support the suggestion
that BEN families are exposed to higher levels of arsenic,
cadmium, selenium, or lead that could contribute to the
occurrence of the disease.
Our study subjects were offspring of BEN patients who are
likely to have a higher susceptibility of their kidneys to
adverse exposures (hypothesis 5). Therefore, we expected
to find that some of the elements would be associated
with kidney function in BEN offspring. However, com-
pared to controls, BEN offspring were not more affected
(Table 4). For lead (Pb) we found a weak association with
creatinine clearance, but only in control offspring. Fur-
ther, since our investigation is based on offspring who
have not yet developed the disease, we believe that this
excluded behavioral changes such as avoidance of chemi-
cals, which could have distorted the results. Therefore,
since prior studies that reported associations between
arsenic/metals and BEN had an ecological design or were
based on geochemistry analyses, our negative findings
suggest that non-epidemiologic studies may have been
misleading.
A limitation of our investigation is the high intra-individ-
ual variance of kidney parameters. If our analysis would
have been based on a single examination, this could have
led to biased results. However, we included repeated
measurements that took intra-individual variances into
account and provided added confidence in our results. In
addition, we focused on more stable indicators and did
not consider clinical markers such as creatinine in urine,
which showed a large variability over time. A second lim-
itation is that offspring of BEN patients were younger
(Table 1) and degenerative kidney disorders often occur in
older people. Hence, it is possible, that we underesti-Environmental Health 2008, 7:11 http://www.ehjournal.net/content/7/1/11
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mated the effect of the metals/metalloids. Thirdly, as out-
lined in the introduction, there are no BEN patients born
in non-BEN villages. Hence a two-way analysis (metals/
metalloids and BEN-village) is not feasible. Since many
new conclusions on what causes BEN have been presented
based on aggregative (village data), we preferred a more
rigorous testing of risk factors and focused on the associa-
tion of metal/metalloids and BEN status within villages
who are labeled BEN villages.
We are not aware of another study that investigated the
association between kidney parameters and selenium in
humans. Nevertheless, a recent study on selenium supple-
mentation found an increased risk for type 2 diabetes
[60]. Based on other findings, we expected that selenium
would have a protective effect (hypothesis 1). However,
we found three unexpected findings: Serum selenium was
associated with increased β2-microglobulin, with
increased kidney length, and decreased CCR. These may
be chance findings. However, the US Agency for Toxic
Substances and Disease Registry lists a number of compa-
rable kidney effects in animals following exposure to sele-
nium at levels several hundred times higher than normal
human intake [38]. Effects include hydropic degeneration
in sheep [61], increases in kidney weights in mice and
ducks [62-64], larger Bowman's capsules and minimal
papilla degeneration of the kidneys in rats [62,65], and
glomerulonephritis and proximal convoluted tubule
nephropathy in long-tailed macaques [66].
Recently, Balkan endemic nephropathy has attracted
some attention [9-11]. First, a number of potential new
risk factors have been presented. Second, its uniqueness in
the Balkan regions has been questioned as similar mani-
festations were observed in other regions too [10], for
instance in Sri Lanka [67]. There is a necessity for carefully
testing various proposed risk factors and pathological
mechanisms. We believe that our study contributes to the
evidence that metals and metalloids are no risk factors for
BEN. Further studies are necessary to test the claim of
other proposed risk factors.
Conclusion
Our results do not support the hypotheses that cadmium,
lead, or arsenic pose a risk for the development of Balkan
Endemic Nephropathy. Against the assumption in the lit-
erature, selenium was not protective, but a risk factor for
all three markers: β2-microglobulin, creatinine clearance,
and kidney length. Since comparable associations with
anatomical and functional markers were observed in ani-
mals, future studies are warranted to investigate selenium
effects on the kidney in humans.
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